Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 9/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 8/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25945712 | 0.89 | MAP4K1 (0.46) | MAP4K1PTGER3ALDH1A1 | |
| SCHEMBL25950670 | 0.87 | MAP4K1 (0.45) | MAP4K1PTGER3PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL25944716 | 0.84 | MAP4K1 (0.41) | MAP4K1PTGER3PARP1PKMSMN1; SMN2 | |
| SCHEMBL21703352 | 0.83 | MAP4K1 (0.50) | MAP4K1PTGER3PARP1ALDH1A1 | |
| SCHEMBL25944728 | 0.80 | MAP4K1 (0.59) | MAP4K1PTGER3ALDH1A1TSHRHSD17B10 | |
| SCHEMBL25944756 | 0.80 | MAP4K1 (0.57) | MAP4K1PTGER3ALDH1A1TSHRHSD17B10 | |
| SCHEMBL25938330 | 0.78 | MAP4K1 (0.56) | MAP4K1PTGER3PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL25944793 | 0.77 | MAP4K1 (0.60) | MAP4K1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL25950538 | 0.76 | MAP4K1 (0.46) | MAP4K1PTGER3PKMSMN1; SMN2CYP1A2 | |
| SCHEMBL23453075 | 0.74 | MAP4K1 (0.70) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |